1. Home
  2. Media
  3. News
  4. Bioiberica Animal Health presents their latest scientific advances in the most important meetings in the veterinary field

Bioiberica Animal Health presents their latest scientific advances in the most important meetings in the veterinary field

26 Jul 2016
Companion Animal Health

The Animal Health Division leads important scientific studies in the fields of internal medicine, dermatology and veterinary traumatology 

Bioiberica’s Animal Healthcare Division presented the results of their most recent research in the most recent conferences that they have attended. The first one was the 8th World Congress on Veterinary Dermatology, which was held in early June in Bordeaux. Bioiberica presented in this conference the results of two research projects about the topical treatment of atopic dermatitis in dogs. The first one confirmed the anti-inflammatory effect of sphingomyelin, while the second one confirmed the clinical efficacy and safety of a combination of glycosaminoglycans and sphingolipids for the topical treatment of atopic dermatitis. This combination will be included in the formulation of Atopivet, which Bioiberica Animal Health will launch soon.

In July, Bioiberica presented at the Congress of the ECVS (European College of Veterinarian Surgeons) in Lisbon the results of a study on the use of orally administered Hyal-Joint for the treatment of anterior cruciate ligament tears. This study proved that the post-surgery oral administration of hyaluronic acid (Hyal-Joint) promotes an increase in intra-articular hyaluronic acid and the reduction of haptoglobin levels. These results confirm the bio-availability of orally administered hyaluronic acid in dogs, and that the active ingredient efficiently reaches the articular tissues. The study’s data would also suggest a possible anti-inflammatory effect of hyaluronic acid.

Finally, Bioiberica’s Animal Health Division was also present at the ICNIM Congress (International Congress in Nutrition and Integrative Medicine) held in Sapporo (Japan) on 9-10 July 2016. In this congress, Sergi Segarra, head of the R&D department of the Animal Health Division, presented a study on the efficacy and safety of the combination of Impromune (nucleotides and AHCC) and Glucantime for the treatment of canine leishmaniosis, comparing results with those obtained by the standard treatment (allopurinol with Glucantime). The combination with Impromune proved to be as effective as the standard treatment, even superior in some aspects, avoiding the secondary effects of the standard treatment. These are especially important results, if we take into account that leishmaniosis is a zoonosis that is present worldwide, and that the control of canine leishmaniosis is of utmost importance to reduce the number of cases of leishmaniosis in humans. The current treatment is not 100% effective and causes undesired side effects. Therefore, the use of Impromune could be a valid alternative.